Albany, NY -- (SBWire) -- 04/12/2019 --Urinary tract infection (UTI) is a microbial infection caused by bacteria, fungi, and in rare cases by viruses. The urinary tract comprises kidneys, ureters, bladder, and urethra. Most UTIs only involve the urethra and bladder in the lower tract. Urinary tract infection is a life-threatening disease due to transmission of the infection from kidney to blood which causes urosepsis, with symptoms such as dangerously low blood pressure, shock, and death. The type of antibiotics prescribed depends on what part of the tract is to be treated. However, developments in route of administration and different concentration of drugs enable prevention of the disease or infection to spread at the cellular and molecular level.

View Report: https://www.transparencymarketresearch.com/urinary-tract-infection-market.html

High prevalence of diseases such as diabetes and kidney stone, increase in incidence of urinary tract infection among adults, surge in patient awareness, rise in research and development initiatives, advent of high-throughput screening (HTS) for drug discovery, and FDA approvals for drugs are the major factors driving the global urinary tract infection market. According to the Nature Reviews Microbiology (2016), urinary tract infections are the most common bacterial infections, affecting 150 million people each year globally. Currently, the societal cost of these infections, including health care costs and time missed from work, is approximately US$ 3.5 Bn per year in the U.S. alone. The rate of infection burden can be reduced through early detection of urinary tract infection and management of patients who develop kidney stone. Increase in the number of patients with chronic diseases, rise in the geriatric population, surge in awareness about minimally invasive techniques, and FDA approval of drugs are projected to fuel the growth of the global urinary tract infection market. However, factors such as increasing incidence of cancer and cost of diagnosis are expected to hamper the growth of the global urinary tract infection market.

The global urinary tract infection market can be segmented based on drug, route of administration, distribution channel, and region. In terms of drug, the urinary tract infection market can be classified into quinolones, penicillin & combinations, cephalosporin, azoles & amphotericin B, sulphonamides, aminoglycoside-antibodies, nitrofurans, and tetracycline. Based on route of administration, the global urinary tract infection market can be categorized into intravenous, oral, and others. Oral is a fast growing segment owing to increase in rate of infection of the upper tract UTI among patients. In terms of distribution channel, the urinary tract infection market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies.

Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=61536

In terms of region, the global urinary tract infection market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2017 due to increase in funding for the development of research and health care infrastructure. Increase in incidence of urinary tract infections and early diagnosis and treatment of diseases drive the medical biotechnology segment, which in turn is projected to boost the growth of the urinary tract infection market in North America.

Europe is the second largest market for urinary tract infection treatment, due to favorable government policies toward development of health care infrastructure and pharmaceutical companies. The urinary tract infection market in Asia Pacific is expected to expand at a high CAGR during the forecast period due to rise in population with urinary tract infection, surge in awareness among patients, and increase in per capita expenditure. Additionally, economic growth in India and China supports the health care infrastructure as well as expansion of pharmaceutical companies and biotech labs.

Request TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=61536

Major players operating in the global urinary tract infection market are Pfizer, Inc., AstraZeneca plc, Novartis AG., Johnson & Johnson, F. Hoffmann La-Roche Ltd., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, and Cipla Ltd., and Rempex Pharmaceuticals, among others.

About Transparency Market Research
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR's syndicated reports strive to provide clients to serve their overall research requirement.

Contact Us
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com